KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) EBIT (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed EBIT for 13 consecutive years, with $211.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 373.07% to $211.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$51.7 million, a 81.48% increase, with the full-year FY2025 number at -$51.7 million, up 81.48% from a year prior.
  • EBIT was $211.6 million for Q4 2025 at Xenon Pharmaceuticals, up from -$96.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $211.6 million in Q4 2025 to a low of -$96.3 million in Q3 2025.
  • A 5-year average of -$34.8 million and a median of -$51.4 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 3382.66% in 2021, then surged 373.07% in 2025.
  • Xenon Pharmaceuticals' EBIT stood at $32.9 million in 2021, then tumbled by 231.89% to -$43.3 million in 2022, then decreased by 23.92% to -$53.7 million in 2023, then tumbled by 44.29% to -$77.5 million in 2024, then soared by 373.07% to $211.6 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's EBIT are $211.6 million (Q4 2025), -$96.3 million (Q3 2025), and -$94.2 million (Q2 2025).